Aquestive Therapeutics/$AQST
13:30
14:25
15:15
16:10
17:00
1D1W1MYTD1Y5YMAX
About Aquestive Therapeutics
Aquestive Therapeutics Inc is a specialty pharmaceutical company engaged in developing and commercializing differentiated products to meet medical needs. Its later-stage product pipeline focuses on the treatment of diseases of the Central Nervous System (CNS), and an earlier-stage pipeline for the treatment of severe allergic reactions, including anaphylaxis. Its commercial product portfolio includes Suboxone, Emylif, Ondif and Sympazan. The product pipeline includes Libervant Buccal Film, AQST-108. The majority of its revenue comes from the United States.
Ticker
$AQST
Sector
Primary listing
Industry
Pharmaceuticals
Headquarters
Employees
142
ISIN
US03843E1047
Website
AQST Metrics
BasicAdvanced
$369M
-
-$0.59
2.02
-
Price and volume
Market cap
$369M
Beta
2.02
52-week high
$5.48
52-week low
$2.12
Average daily volume
1.5M
Financial strength
Current ratio
4.873
Quick ratio
4.323
Long term debt to equity
-63.299
Total debt to equity
-64.229
Interest coverage (TTM)
-2.44%
Profitability
EBITDA (TTM)
-40.506
Gross margin (TTM)
68.40%
Net profit margin (TTM)
-100.02%
Operating margin (TTM)
-75.94%
Effective tax rate (TTM)
0.03%
Revenue per employee (TTM)
$380,000
Management effectiveness
Return on assets (TTM)
-22.21%
Return on equity (TTM)
111.57%
Valuation
Price to revenue (TTM)
6.325
Price to book
-6.06
Price to tangible book (TTM)
-6.06
Price to free cash flow (TTM)
-6.994
Free cash flow yield (TTM)
-14.30%
Free cash flow per share (TTM)
-53.19%
Growth
Revenue change (TTM)
5.29%
Earnings per share change (TTM)
34.24%
3-year revenue growth (CAGR)
1.42%
3-year earnings per share growth (CAGR)
-30.42%
What the Analysts think about AQST
Analyst ratings (Buy, Hold, Sell) for Aquestive Therapeutics stock.
Bulls say / Bears say
Positive Phase 3 results for Anaphylm, an epinephrine sublingual film, and FDA approval for Libervant indicate strong product pipeline progress. (Investing.com)
Analysts project significant upside potential, with Cantor Fitzgerald initiating coverage with an 'Overweight' rating and a $17 price target, suggesting over 200% potential increase upon Anaphylm's approval. (Benzinga)
Institutional investors, including Vanguard Group and Geode Capital Management, have increased their holdings, reflecting confidence in the company's prospects. (ETF Daily News)
The company reported a net loss of $12.8 million in Q1 2024, a decline from net income in the same period the previous year, indicating financial challenges. (Investing.com)
Research and development expenses increased from $3.5 million to $5.9 million, and selling, general, and administrative expenses rose from $7.5 million to $10.7 million, potentially impacting profitability. (Investing.com)
Lake Street Capital lowered its price target from $10.00 to $8.00, indicating tempered expectations for the stock's performance. (Techdows News)
Data summarised monthly by Lightyear AI. Last updated on 4 Jun 2025.
AQST Financial Performance
Revenues and expenses
AQST Earnings Performance
Company profitability
AQST News
AllArticlesVideos
Aquestive Therapeutics to Present Positive Data from Pharmacokinetic and Pharmacodynamic Studies of Anaphylm™ (epinephrine) Sublingual Film at the CFAAR Food Allergy Summit
GlobeNewsWire·1 week ago
Aquestive Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update
GlobeNewsWire·2 months ago
Aquestive Therapeutics to Participate in Piper Sandler Spring Biopharma Symposium
GlobeNewsWire·3 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Aquestive Therapeutics stock?
Aquestive Therapeutics (AQST) has a market cap of $369M as of July 04, 2025.
What is the P/E ratio for Aquestive Therapeutics stock?
The price to earnings (P/E) ratio for Aquestive Therapeutics (AQST) stock is 0 as of July 04, 2025.
Does Aquestive Therapeutics stock pay dividends?
No, Aquestive Therapeutics (AQST) stock does not pay dividends to its shareholders as of July 04, 2025.
When is the next Aquestive Therapeutics dividend payment date?
Aquestive Therapeutics (AQST) stock does not pay dividends to its shareholders.
What is the beta indicator for Aquestive Therapeutics?
Aquestive Therapeutics (AQST) has a beta rating of 2.02. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.